Clinician and patient HSP outcomes compared

The SPRS alone showed clinical progression

The Spastic Paraplegia Rating Scale (SPRS) is an HSP-specific clinician-reported outcome measure (CROM). It was the only measure that showed the clinical progression that had taken place over a year in this study of 55 people with HSP.

There are no specific patient-reported outcome measures (PROM) for HSP, and unsurprisingly, the PROMs used in the study failed to detect change in HSP status over the year.

The study authors propose creating a disease-specific PROM fully depicting the effect of HSP on the lives of people with HSP.

Background and objectives: Hereditary spastic paraplegias (HSPs) are a heterogeneous group of rare neurodegenerative diseases, characterized by a progressive spastic paraparesis. Currently, there is a HSP-specific clinician-reported outcome measure (CROM) called Spastic Paraplegia Rating Scale (SPRS). There are, however, no specific patient-reported outcome measures (PROMs) for HSP. In the present cohort study, we prospectively follow up a well-examined Austrian HSP cohort using validated rating scales and compared PROM with disease-specific and non-disease-specific CROM.

Methods: Patients were recruited and followed up at the Center for Rare Movement Disorders, Innsbruck, Austria. CROM included the SPRS, Scale for the Assessment and Rating of Ataxia (SARA), Barthel Index (BI), and Mini-Mental State Examination (MMSE). PROM included the EQ-5D questionnaire and the Patient Health Questionnaire 9 (PHQ-9). Standardized response means (SRMs) were calculated for all scales at follow-up (FU) after 1 year.

Results: A total of 55 patients (36 males) with HSP were included in the study. FU was performed for 30 patients (21 males). Apart from females reporting more problems in the EQ-5D domain of anxiety and depression (p = 0.008), other clinician-reported outcomes (CROs) or patient-reported outcomes (PROs) did not differ significantly across sex. SPRS showed significant correlations with SARA (p < 0.001), mainly driven by the gait item, as well as the BI. Although SPRS did not correlate with EQ-5D visual analogue scale and PHQ-9 scores, several EQ-5D domains correlated significantly with SPRS. At FU, SPRS showed the highest responsiveness (SRM 1.11), followed by SARA (SRM 0.47). Neither MMSE nor PRO significantly increased at FU.

Discussion: In this study, we present an Austrian cohort of patients with HSP and a prospective study evaluating correlations of CRO and PRO as well as their progression. Demographics from our cohort are comparable with several other European cohort studies. Our data highlight the capabilities of the SPRS to show clinical progression and warrant consideration of ataxia rating scales such as SARA in HSP cohorts. We also show that the generic PROMs are not suitable to detect change in HSP, and thus, we propose to create a disease-specific PROM fully depicting the effect of HSP on the patients’ lives.

SOURCE:  Neurol Genet. 2023 Jan 10;9(1):e200052. doi: 10.1212/NXG.0000000000200052. eCollection 2023 Feb. PMID: 36636734 Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Toward the Definition of Patient-Reported Outcome Measurements in Hereditary Spastic Paraplegia

Matthias Amprosi  1 Elisabetta Indelicato  1 Andreas Eigentler  1 Josef Fritz  1 Wolfgang Nachbauer  1 Sylvia Boesch  1

1. Centre for Rare Neurological Diseases (M.A., E.I., A.E., W.N., S.B.), Department of Neurology, Medical University of Innsbruck; and Department of Medical Statistics (J.F.), Informatics and Health Economics, Medical University of Innsbruck, Innsbruck, Austria.

Your email address will not be published. Required fields are marked *